IMMH001, also called SYL930, is an orally active, potent and selectiveS1P1(sphingosine-1-phosphate receptor 1) agonist. IMMH001 decreased levels of both chemokines and proinflammatory cytokines, including IL-1β,IL-5,IL-18, IP10, CCL3, and CCL5. IMMH001 can be used for rheumatoid arthritis (RA) research^[1][2].

IMMH001 is converted to the active form, its monophosphate ester (S)-IMMH001-P, by sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2)in vivo^[1].
IMMH001 suppresses both Th1 cell (IL-1β, IL-18, and IP10) and Th2 cell (IL-5)-mediated disease reactions in damaged joints^[2].
IMMH001 (0.3-2.4 mg/kg, Orally; twice a week, for 28 days, AA rats; for 30 days, CIA rats) relieves the damage of AA (adjuvant-induced arthritis) and CIA (collagen-induced arthritis) rats’ joints^[2].

380.48

C₂₃H₂₈N₂O₃

1418093-75-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.